Lymphocyte migration and multiple sclerosis: Relation with disease course and therapy

Alexandre Prat*, Abdulla Al-Asmi, Pierre Duquette, Jack P. Antel

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

51 Citations (Scopus)


Lymphocyte migration into the central nervous system is a central event in lesion formation in multiple sclerosis. By using a fibronectin-coated membrane Boyden chamber assay, we observed that migration rates of immediately ex vivo lymphocytes from patients with relapsing-remitting, with or without concurrent clinical relapse, or with secondary progressive disease, were increased compared with healthy donors. Migration rates of lymphocytes from relapsing-remitting multiple sclerosis patients receiving either glatiramer acetate (Copaxone 20 mg daily) or interferon-β1b (Betaseron 8 MIU, three times per week) were significantly reduced compared with untreated relapsing-remitting patients. In vitro treatment with interferon-β1b (1,000 U/ml), but not glatiramer acetate (20 μg/ml), significantly reduced lymphocyte-migration rates, suggesting that the effects of these two therapeutic agents on migration result from different mechanisms of actions. Interferon-β1b acts, at least in part, by a direct effect on this cell property, whereas glatiramer acetate effects are indirect.

Original languageEnglish
Pages (from-to)253-256
Number of pages4
JournalAnnals of Neurology
Issue number2
Publication statusPublished - 1999
Externally publishedYes

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Lymphocyte migration and multiple sclerosis: Relation with disease course and therapy'. Together they form a unique fingerprint.

Cite this